NuvOx Pharma

1635 E 18th Street
Tucson
Arizona
85719
United States

Tel: 520-624-6688
Fax: 520-624-6699

About NuvOx Pharma

NuvOx Pharma is a biotechnology company based in Tucson, Arizona with a novel patent portfolio allowing it to develop an innovative platform of dodecafluoropentane (DDFP)-based oxygen therapeutics to treat a host of human conditions. Founded in 2008, NuvOx Pharma has demonstrated therapeutic feasibility in radiation-resistant cancer, hemorrhagic shock, traumatic brain injury, myocardial infarction, retinopathy and stroke. Due to inherent structure of DDFP, a very stable and relative lack of inter-molecular attractive forces, this perfluorocarbon is known to carry large payloads of oxygen in the bloodstream. The main advantage to using DDFP is that it is a liquid at room temperature, but expands to the gas state in the body. Therefore, upon intravenous injection the transition of DDFP from a liquid to a gas in the bloodstream allows for ~600 times increased oxygen transport compared to Hemoglobin.

YEAR FOUNDED:
2008
LEADERSHIP:
Founder and CEO: Evan C. Unger
CFO: Betty R Weaver
COO: Rajan Ramaswami
JOBS:
Please click here for NuvOx job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.

9 articles about NuvOx Pharma

NuvOx Completes Construction of Expanded Manufacturing Facility.

4/30/2021

NuvOx Pharma has completed construction and initiated operation of its GMP production facility for manufacturing its injectable pharmaceutical products at its Tucson, Arizona facility.
Health Canada Allows COVID-19 Patients with Respiratory Failure to Be Given NuvOx Pharma's Oxygen Therapeutic in Phase IIa Clinical Trial

6/30/2020

NuvOx Pharma, a Tucson-based biotechnology company developing NanO2™ emulsion for oxygen delivery, has received a “No Objection Letter” from Health Canada to proceed with a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF).
NuvOx Pharma’s NVX-208 Shows Positive Results in Phase Ib/II Stroke Trial

2/8/2019

Positive results of NuvOx Pharma’s NVX-208 in the treatment of stroke have been published at the International Stroke Conference.
FDA Allows a Phase II Clinical Trial in Stroke for NuvOx Pharma’s DDFPe

1/31/2018

NuvOx Pharma announces that the FDA has allowed a Phase II clinical trial in 60 stroke patients to proceed to test NuvOx’s investigational drug product, dodecafluoropentane emulsion (DDFPe).
NCI Awards Grant To NuvOx Pharma For Phase II Clinical Trial In Brain Cancer

9/29/2017
NuvOx Pharma: Breathing New Life Into An Old Contrasting Agent

6/5/2017
FDA Allows NuvOx Pharma To Run A Phase II Clinical Trial In Brain Cancer

4/13/2017
NuvOx Pharma And University of Arkansas Initiate Phase Ib/II Clinical Trial In Stroke

3/8/2017
NuvOx Pharma And The University of Arkansas Initiate Phase Ib/II Clinical Trial In Stroke

3/6/2017